BBS Faculty Member - Daniel Haber

Daniel Haber

Department of Medicine

Massachusetts General Hospital East
MGH Cancer Center
149 13th Street
Charlestown, MA 02129
Tel: 617-726-7805
Fax: 617-724-6919
Email: dhaber@mgh.harvard.edu
Lab Members: 9 postdoctoral fellows, 1 graduate student
Visit my lab page here.



Our laboratory is interested in the genetics of human cancer. Current projects include the use of a microfluidic device to capture circulating tumor cells (CTCs) and its application in molecular-directed therapy and in the study of human cancer metastasis.

Activating mutations in the epidermal growth factor receptor (
EGFR) were identified in our laboratory in the subset of non-small cell lung cancer (NSCLC) with dramatic responses to the tyrosine kinase inhibitor gefitinib. We have studied mechanisms underlying such oncogene addiction, as well as the pathways that lead to the acquisition of resistance to targeted therapies, including the application of irreversible kinase inhibitors to circumventing mutations that alter drug binding affinity. Following on our efforts to monitor the emergence of drug resistance mutations, we are now collaborating with the Toner and Maheswaran laboratories to characterize novel microfluidic devices capable of isolating CTCs from the blood of cancer patients. Our most advanced version of these CTC-Chips relies upon blood flow through a specialized chamber, which allows the high efficiency separation of antibody-tagged leukocytes, thereby identifying intact CTCs without selection bias. In a series of CTC studies, we have shown that the number of captured CTCs correlates with clinical evidence of tumor response, and that the cells can be used to define molecular markers characteristic of the underlying malignancy, including EGFR mutations and EML4-ALK translocations in lung cancer, and measurements of androgen receptor (AR) activity in prostate cancer. We have applied next generation single-molecule RNA sequencing to identify non-canonical Wnt signaling as a suppressor of anoikis pathways in circulating pancreatic cancer cells, while in melanoma and in glioblastoma, we developed tools to isolate and molecularly characterize CTCs.

Our most recent studies have focused on breast cancer, where we demonstrated treatment-associated epithelial-to-mesenchymal transition (EMT) within CTCs. Using a combination of mouse models and patient-derived studies, we observed that tumor-derived fragments generate CTC-Clusters, which have greatly enhanced metastatic propensity compared with single CTCs. CTC-Clusters are held together by plakoglobin, whose knockdown dramatically suppresses CTC-Cluster formation and metastatic spread of breast cancer cells. Finally, we successfully established long-term
in vitro cultures of CTCs from patients with estrogen-receptor positive breast cancer, identifying treatment-associated mutations in the estrogen receptor (ESR1), as well as acquired mutations in drugable therapeutic targets, such as PIK3CA and FGFR. The development of such CTC-derived cultures may enable functional predictive drug testing, combined with detailed genetic analysis of tumor cells sampled noninvasively during the course of cancer treatment.

Current efforts are directed at isolating single CTCs to uncover the heterogeneous nature of these rare metatastic precursors. Further technological improvements in CTC capture and detection are under study for potential applications in early detection of cancer, monitoring tumor genotypes over the course of treatment, and biological characterization of CTCs themselves.



Last Update: 8/4/2015



Publications

For a complete listing of publications click here.

 


 

Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu C-L, Shioda T, Ramaswamy S, Ting DT, Toner M, Maheswaran* S, Haber* DA. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance Science in press, 2015.

Rothenberg SM, Concannon K, Cullen S, Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA, Maheswaran S, Haber DA. Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.
eLife Feb 16: 4 doi: 10.7554/eLife.06132, 2015.

Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramas¬wamy S, Ting DT, Lin CP, Toner M, Haber DA*, Maheswaran S*. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.
Cell. 158(5):1110- 22, 2014.

Yu M, Bardia A, Aceto N, Bersani F, Madden M, Donaldson MC, Desai R, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, Shioda T, Ting, DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C, Toner, M, Maheswaran S* and Haber DA*. Ex vivo culture of circulating breast tumor cells for indi¬vidualized testing of drug susceptibility.
Science. 346(6193): 216-22, 2014.

Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT, Aceto N, Bersani F, Brannigan BW, Xega K, Ciciliano JC, Zhu H, MacKenzie OC, Trautwein J, Arora KS, Shahid M, Ellis HL, Qu N, Bardeesy N, Rivera MN, Deshpande V, Ferrone CR, Kapur R, Ramaswamy S, Shioda T, Toner M, Maheswaran* S, Haber* DA. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells.
Cell Rep. 8(6): 1905-18, 2014

Yu M*, Bardia A*, Wittner BS, Stott SL, SMas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KE, Donaldson MC, Sequist LV, Bracheter E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA* and Maheswaran S*. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesen¬chymal composition.
Science 339: 580-4, 2013.

*Co-corresponding authors



© 2015 by the President and Fellows of Harvard College